NEW YORK (GenomeWeb News) – Biodesix said today it has entered a collaborative agreement with Bruker Daltonics to support its VeriStrat diagnostic test as well as future tests based on MALDI-TOF mass spectrometry.
A serum protein test for identifying non-small cell lung cancer patients likely to respond to various therapies, Veristrat runs on Biodesix's MALDI-TOF-based ProTS platform, which uses Bruker Autoflex and Ultraflextreme instruments.
According to the companies, the collaboration will provide Biodesix with hardware and software support, as well as access to Bruker's latest instrument designs and improvements.
“We are pleased to solidify our relationship with one of our key partners with this new agreement,” Gary Pestano, head of product development and lab operations at Biodesix, said in a statement. “The support we receive from Bruker will substantially benefit both the delivery and development of our diagnostic tests.”
Gary Kruppa, vice president for business development at Bruker Daltonics noted in a statement that the company aimed through its support of Biodesix, to "increase the market for Bruker’s innovative MALDI-TOF mass spectrometers in diagnostics.”
Also today, Biodesix announced it closed on $8.8 million in a follow-on sale of its Series D preferred shares. The funds, all of which were provided by existing shareholders, will be used for development of its technology platform and expanded sales and marketing of the Veristrat test, the company said.
Last August, the Boulder, Colo.-based company raised $12 million in an extension of a Series D financing round.